ICON PLC (ICLR) reported quarterly earnings results on Tuesday, Jul-26-2016. The company reported $1.14 EPS for the quarter. Analysts had a consensus estimate of $1.14. The company posted revenue of $410.60 million in the period, compared to analysts expectations of $409.98 million. The company’s revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.95 EPS.
Many Wall Street Analysts have commented on ICON PLC. ICON PLC was Initiated by Credit Suisse to “Outperform” on Jun 21, 2016. ICON PLC was Downgraded by Avondale to ” Mkt Underperform” on Jun 9, 2016. ICON PLC was Downgraded by Jefferies to ” Hold” on Jun 3, 2016.
ICON PLC opened for trading at $70.54 and hit $72.77 on the upside on Wednesday, eventually ending the session at $71.98, with a gain of 1.93% or 1.36 points. The heightened volatility saw the trading volume jump to 4,07,271 shares. Company has a market cap of $3,964 M.
ICON public limited company (ICON) is an Ireland-based contract research organization (CRO) providing outsourced development services to the pharmaceutical biotechnology and medical device industries. The Company is engaged in the strategic development management and analysis of programs that support the various stages of the clinical development process from compound selection to Phase I-IV clinical studies. ICON’s services include clinical trials management biometric activities consulting imaging contract staffing informatics and laboratory services. ICON also conducts various laboratory tests on the patient’s blood urine and other bodily fluids at appropriate intervals during the trial. The Company’s information systems offerings include ICONIK Firecrest iDOC iLearn ADDPLAN AptivAdvantage and AptivInsite. ICON through its subsidiaries also provides payer-validated market access solutions and clinical trial consulting and regulatory support.